<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="9636" end="9641" sStart="9554" offset="82" sid="r7.1.use.v.0896" wn="1" wnkey="use%2:34:01::" text="Similarly, the feasibility and safety of carotid angioplasty and stenting using the PercuSurge GuardWire system has been determined [ 10]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-286.anc" start="1949" end="1956" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="However, the &lt;b&gt;success&lt;/b&gt; of these medical interventions is most commonly defined by angiographic resolution of the &quot;no-reflow&quot; phenomenon (an acute reduction in coronary flow less than Thrombolysis in Myocardial Infarction [TIMI] 2 in the absence of dissection, thrombus, spasm, or high-grade residual stenosis at the original target lesion)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-286.anc" start="1770" end="1777" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="Limited therapeutic &lt;b&gt;success&lt;/b&gt; has been reported from observational studies involving the use of calcium channel blockers, adenosine, and sodium nitroprusside [ 5]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-286.anc" start="1949" end="1956" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="However, the &lt;b&gt;success&lt;/b&gt; of these medical interventions is most commonly defined by angiographic resolution of the &quot;no-reflow&quot; phenomenon (an acute reduction in coronary flow less than Thrombolysis in Myocardial Infarction [TIMI] 2 in the absence of dissection, thrombus, spasm, or high-grade residual stenosis at the original target lesion)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-286.anc" start="1770" end="1777" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="Limited therapeutic &lt;b&gt;success&lt;/b&gt; has been reported from observational studies involving the use of calcium channel blockers, adenosine, and sodium nitroprusside [ 5]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="19162" end="19168" sStart="null" offset="13" sid="r8.state.n.0098" wn="2147483647" wnkey="null" text="FDA = United States Food and Drug Administration; GP = glycoprotein; MI = myocardial infarction; PAES = Parodi Anti-Emboli System; US = United States." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="19162" end="19168" sStart="null" offset="13" sid="r8.state.n.0098" wn="2147483647" wnkey="null" text="FDA = United States Food and Drug Administration; GP = glycoprotein; MI = myocardial infarction; PAES = Parodi Anti-Emboli System; US = United States." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="19162" end="19168" sStart="null" offset="13" sid="r8.state.n.0098" wn="2147483647" wnkey="null" text="FDA = United States Food and Drug Administration; GP = glycoprotein; MI = myocardial infarction; PAES = Parodi Anti-Emboli System; US = United States." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="19162" end="19168" sStart="null" offset="13" sid="r8.state.n.0098" wn="2147483647" wnkey="null" text="FDA = United States Food and Drug Administration; GP = glycoprotein; MI = myocardial infarction; PAES = Parodi Anti-Emboli System; US = United States." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="6785" end="6791" sStart="null" offset="9" sid="r7.serve.v.0348" wn="1" wnkey="serve%2:42:03::" text="The wire serves as both the angioplasty guidewire and provides protection from distal embolization." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-286.anc" start="5804" end="5808" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" text="Carotid angioplasty and stenting is associated with a perioperative stroke &lt;b&gt;rate&lt;/b&gt; exceeding 3% in most series, largely due to emboli." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-286.anc" start="5804" end="5808" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" text="Carotid angioplasty and stenting is associated with a perioperative stroke &lt;b&gt;rate&lt;/b&gt; exceeding 3% in most series, largely due to emboli." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="18225" end="18230" sStart="null" offset="67" sid="r8.1.great.j.0621" wn="1" wnkey="great%5:00:01:large:00" text="There is nothing controversial or subtle, however, about a great many of the embolic infarctions that occur during vein graft or carotid interventions." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="6333" end="6344" sStart="null" offset="171" sid="r1.development.n.0043" wn="" wnkey="null" text="A number of distal protection devices that aim to reduce or eliminate distal embolization during percutaneous coronary and carotid interventions are under development (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="6333" end="6344" sStart="null" offset="171" sid="r1.development.n.0043" wn="1" wnkey="development%1:04:01::" text="A number of distal protection devices that aim to reduce or eliminate distal embolization during percutaneous coronary and carotid interventions are under development (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="6333" end="6344" sStart="null" offset="171" sid="r1.development.n.0043" wn="7" wnkey="development%1:26:00::" text="A number of distal protection devices that aim to reduce or eliminate distal embolization during percutaneous coronary and carotid interventions are under development (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="9174" end="9180" sStart="null" offset="184" sid="r10.common.j.0147" wn="4" wnkey="common%5:00:00:familiar:02" text="Interestingly, although GP IIb/IIIa inhibitors were used in &gt;60% of all patients, predominantly before intervention, major adverse clinical events were more common amongst those receiving the drug." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="8918" end="8923" sStart="null" offset="66" sid="r10.board.n.0223" wn="1" wnkey="board%1:14:00::" text="The trial was stopped early by the data safety monitoring board, and the manufacturer promptly secured FDA approval." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="3401" end="3408" sStart="null" offset="166" sid="r11.benefit.n.0463" wn="2" wnkey="benefit%1:07:00::" text="Despite suggestion of benefit as measured by surrogate angiographic endpoints, there is no evidence of a consistent and sustained meaningful clinical benefit [ 7, 8]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="3012" end="3020" sStart="null" offset="6" sid="r11.benefit.n.0133" wn="2" wnkey="benefit%1:07:00::" text="These benefits, however, have been apparent in subset analyses of clinical trials, or in observational studies designed to specifically assess their efficacy in saphenous vein graft interventions." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="2726" end="2733" sStart="null" offset="4" sid="r11.benefit.n.0542" wn="2" wnkey="benefit%1:07:00::" text="The benefit is thought to be, in part, due to a reduction in the incidence of ischemic complications, which is likely to be secondary to prevention of platelet aggregation, thrombus formation, and distal embolization, in native coronary arteries [ 6]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="3483" end="3490" sStart="null" offset="57" sid="r11.benefit.n.0288" wn="2" wnkey="benefit%1:07:00::" text="The likely explanation for this apparent lack of benefit in vein graft interventions, when GP IIb/IIIa inhibitors clearly reduce procedural infarctions by approximately 50%, is the difference in the composition of the embolic material." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-286.anc" start="2203" end="2210" sStart="null" offset="277" sid="r11.absence.n.0842" wn="1" wnkey="absence%1:26:00::" text="However, the success of these medical interventions is most commonly defined by angiographic resolution of the &quot;no-reflow&quot; phenomenon (an acute reduction in coronary flow less than Thrombolysis in Myocardial Infarction [TIMI] 2 in the absence of dissection, thrombus, spasm, or high-grade residual stenosis at the original target lesion)." />
  </sentences>
</list>